InnoSino Biopharma is a Shanghai-based biotechnology company developing innovative therapies for neurodegenerative diseases, with a primary focus on Parkinson's disease (PD) and Alzheimer's disease (AD). Founded in 2015, InnoSino has established itself as a leading Chinese biotech focused on protein-targeting approaches including monoclonal antibodies and small molecule inhibitors that address the underlying pathological mechanisms of neurodegeneration.
The company's name "InnoSino" reflects its dual identity—"Inno" represents innovation in biotechnology, while "Sino" indicates its Chinese heritage and commitment to advancing neuroscience research in China. InnoSino operates from state-of-the-art research facilities in the Shanghai Zhangjiang Hi-Tech Park, one of China's premier biotechnology hubs, with additional operations in the Suzhou Industrial Park[程建军2024].
| Attribute | Value |
|---|---|
| Headquarters | Shanghai, China |
| Founded | 2015 |
| Focus | Small molecule drugs, immunotherapy |
| Employees | ~120 (as of 2024) |
| Stage | Clinical (Phase 1) |
InnoSino benefits from its strategic location in the Yangtze River Delta, one of China's most developed biopharmaceutical clusters. The company maintains close relationships with leading Chinese academic institutions including Fudan University, Shanghai Institute of Materia Medica (SIMM), and the Chinese Academy of Sciences.
InnoSino's primary therapeutic approach targets alpha-synuclein (α-syn), the protein that forms the characteristic Lewy bodies found in the brains of Parkinson's disease patients[@spillantini2000; @braak2003]. The company's innovative platform addresses both antibody-based and small molecule approaches to α-syn pathology:
The rationale for α-syn targeting is strong, as aggregation of this protein into toxic oligomers and fibrils is central to PD pathogenesis and correlates with disease progression[@mccann2016].
In addition to α-syn approaches, InnoSino is developing inhibitors of leucine-rich repeat kinase 2 (LRRK2), a protein kinase that has been genetically linked to both familial and sporadic Parkinson's disease. Pathogenic LRRK2 mutations cause increased kinase activity, leading to disruptions in cellular processes including autophagy, lysosomal function, and synaptic transmission[@berman2018].
The company has also expanded into Alzheimer's disease through development of anti-tau antibodies and phosphorylation inhibitors. Tau pathology represents a complementary target to amyloid-based approaches, with tau neurofibrillary tangles correlating more closely with cognitive decline than amyloid plaques.
InnoSino recognizes the critical role of neuroinflammation in neurodegenerative disease progression and has established programs targeting microglial modulation and anti-inflammatory pathways[@heneka2015].
ISB-101 is InnoSino's lead clinical candidate—a monoclonal antibody designed to selectively bind pathological alpha-synuclein species.
ISB-101 targets a conformation-specific epitope present on aggregated α-syn but not on normal monomeric protein. This selective targeting enables:
The antibody was generated using the company's proprietary platform combining phage display library screening and humanization techniques.
The Phase I study demonstrated favorable safety and pharmacokinetic profiles, with dose-proportional exposure and target engagement as measured by cerebrospinal fluid biomarkers.
The Phase Ib study is evaluating:
ISB-202 is InnoSino's small molecule LRRK2 inhibitor program, currently in IND-enabling studies.
LRRK2 inhibitors work by:
The compound has demonstrated excellent brain penetration in preclinical models, with target engagement confirmed at doses achieving plasma concentrations below the no-observed-adverse-effect level (NOAEL).
ISB-301 is InnoSino's Alzheimer's disease program, an antibody targeting pathological tau species.
InnoSino has established a comprehensive antibody discovery platform:
The company's medicinal chemistry team maintains:
InnoSino has invested significantly in biomarker development to support patient selection and clinical endpoints:
InnoSino maintains research collaborations with leading Chinese institutions:
InnoSino is strategically establishing international presence:
InnoSino competes with several global companies in the Parkinson's disease immunotherapy space:
| Company | Product | Mechanism | Status |
|---|---|---|---|
| Roche/Genentech | Prasinezumab | Anti-α-syn antibody | Phase II |
| Biogen | BIIB054 | Anti-α-syn antibody | Phase II |
| Prothelia | PRX002 | Anti-α-syn antibody | Phase II |
| Alector | AL001 | Progranulin modulator | Phase II |
| InnoSino | ISB-101 | Anti-α-syn antibody | Phase I |
InnoSino differentiates through:
| Round | Year | Amount | Lead Investors |
|---|---|---|---|
| Series A | 2015 | $8M | Sinopharm Capital, ZhenFund |
| Series B | 2018 | $25M | Qiming Venture, Hillhouse Capital |
| Series C | 2022 | $45M | Hillhouse Capital, Sequoia China |
| Series D | 2024 | $30M | GIC, Source Code Capital |
Total raised: $108M
InnoSino's long-term strategy includes: